Review: SGLT2 Inhibitors Provide Clear Renal Benefits in Type 2 Diabetes
New review identifies benefits of sodium-glucose co-transporter-2 (SGLT2) inhibitors at almost all levels of kidney function.
Diagnosis & Disease Information
Machine Learning Algorithms Promising in Kidney Diagnostics
Machine learning algorithms can aid in assessment of renal histopathology
Periop Diabetic Ketoacidosis Seen in Patients on SGLT2 Inhibitors
Testing for acid load needed in patients with diabetes taking sodium-glucose cotransporter-2 inhibitors
Kidney Disease Care for Type 2 Diabetics: Dawn of a New Era?
Studies document renal benefits of canagliflozin, dapagliflozin, empagliflozin, and dulaglutide
Esaxerenone Improves Microalbuminuria in Type 2 Diabetes
In a phase 2 study of patients with early diabetic nephropathy, esaxerenone decreased microalbuminuria in a dose-dependent manner over 12 weeks compared with placebo.
Dulaglutide Reduces CV Events, Renal Progression in Type 2 Diabetes
In the REWIND trial of type 2 diabetes patients, dulaglutide modestly reduced cardiovascular events and progression of kidney disease for at least 5 years.
Ertugliflozin Linked to Better Renal Function in Type 2 Diabetes
Ertugliflozin may be protective of renal function in patients with type 2 diabetes.
Dapagliflozin Shown to Slow Diabetic Kidney Disease Progression
Protective effect is driven largely by a sustained 40% decrease in estimate glomerular filtration rate to below 60 mL/min/1.73 m2.
ADA Updates Diabetic Nephropathy Recommendations
Per the ADA update, clinicians should consider prescribing a SGLT2 inhibitor in type 2 diabetes patients with diabetic nephropathy.
Nearly Half of Type 2 Diabetics Have Undiagnosed CKD
Undiagnosed chronic kidney disease is present in 49% of patients with type 2 diabetes mellitus in the United States, a study found.
- Loading...
Loading...
Next post in NKF 2019 Spring Conference
Loading... 
Loading...